A recent multi-institutional study analyzed tumor and plasma biopsies from 18 patients with RET-rearranged NSCLC after treatment with selpercatinib and pralsetinib to characterize mechanisms of acquired resistance. The gene discussed is RET; the disease is neoplasm.